Quoin Sees Four of Six Pediatric Netherton Syndrome Patients Improve
QNRX•Four of six pediatric Netherton Syndrome patients treated with QRX003 achieved ‘Improved’ or ‘Significantly Improved’ outcomes, including one with full five-grade IGA recovery; no treatment-related adverse events were reported across 3-week to 15-month durations. Two additional patients enroll in June and September, with comprehensive data due soon.
1. Clinical Efficacy Outcomes
Four of six children in the compassionate use program were classified as ‘Improved’ or ‘Significantly Improved’ from baseline across key clinical endpoints. One patient achieved a full five-grade improvement on the Investigator’s Global Assessment scale, moving from severe to clear over nine months and remaining clear at 15 months.
2. Treatment Duration and Patient Details
All six participants are under 10 years old, with the youngest infant aged six months. Treatment durations span from three weeks—during which the infant saw emollient use drop from 12 times daily to almost none—to 15 months for the longest-treated responder.
3. Safety and Adverse Events
No treatment-related adverse events have been reported among any participants to date. Monitoring of hematological and skin safety parameters has shown no safety signals across the cohort.
4. Enrollment and Data Release Plans
An additional patient joined on June 15 and two more are scheduled to begin treatment by the end of September. Quoin plans a comprehensive release of program data alongside results from ongoing Phase 2 studies in the coming months.
